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Abstract Sepsis is a major health problem and a leading
cause of death worldwide. In recent years, a crescendo of
attention has been directed to the mechanisms of cell death
that develop during this disease, since these are viewed as
important contributors to the proinflammatory and anti-
inflammatory responses associated with poor outcome.
Here we discuss mechanisms of cell death evident severe
bacterial infection and sepsis including necrosis, apoptosis,
pyroptosis, and extracellular trap-associated neutrophil
death, with a particular emphasis on lymphocyte apoptosis
and its contribution to the immunosuppressed phenotype of
late sepsis. Individual bacterial pathogens express viru-
lence factors that modulate cell death pathways and
influence the sepsis phenotype. A greater knowledge of cell
death pathways in sepsis informs the potential for future
therapies designed to ameliorate immune dysfunction in
this syndrome.
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Introduction
Sepsis remains the leading cause of death in intensive care
units (ICUs), despite remarkable advances in treatment of
critical illness and outstanding progress in all other aspects
of ICU medicine [1]. Current mortality rates attributable to
sepsis are in the 30–40% range and increase to *70% in
specific patient groups such as the elderly and those with
chronic underlying diseases. These disappointing statistics
reflect the multiplicity of agonistic and antagonist inter-
actions between bacterial pathogens and host cells, yielding
complex inflammatory responses during the course of
disease that are far from completely understood. Indeed,
only by probing deeper into the molecular and cellular
mechanisms that trigger the clinical features observed in
sepsis patients can we anticipate the development of more
effective medicines and improved survival.
Sepsis, according to the actual consensus, is a disease
defined by clinical criteria. These criteria were defined by
specialists in the field, who joined in 1991 for a meeting
organized by the ‘‘American College of Chest Physicians’’
and by the ‘‘Society of Critical Care Medicine’’, aimed to
standardize the nomenclature, which was becoming con-
fusing, due to the indiscriminate use of terms as bacteremia,
septicemia and sepsis [2]. The currently accepted nomen-
clature defines sepsis as a systemic inflammatory response
syndrome (SIRS) due to infection and characterized by the
presence of at least two parameters: hypothermia or fever,
tachycardia, leukocytosis or leukopenia, or more than 10%
immature leukocytes in the blood. ‘‘Severe sepsis’’ is rec-
ognized by the presence of organ dysfunction plus evidence
of blood perfusion abnormalities (e.g., lactic acidosis, oli-
guria, altered consciousness) and episodes of hypotension,
while ‘‘septic shock’’ exists when blood perfusion abnor-
malities are not responsive to vigorous fluid administration.
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Septic shock typically leads to multiple organ dysfunction
syndrome (MODS), where failure of three or more organ
systems develops in the critically ill patient and homeostasis
cannot be maintained without life support techniques.
In the 1980s, prevailing thought attributed the high
mortality of sepsis to an explosive and overwhelming
systemic inflammatory response. In these models, bacterial
components would hyper-activate the immune system,
inducing an inflammatory response so potent that it could
eventually lead the host to die. This hypothesis inspired
several clinical trials aiming to down-regulate and control
inflammation, e.g., with high dose corticosteroids or anti-
cytokine agents. The disappointing results of such trials,
indeed in some cases mortality was even increased by the
anti-inflammatory strategies, revealed that the proposed
concept was wrong, or at least incomplete, and certainly
underappreciated the fact that sepsis is a heterogeneous
disease, affecting both young and the elderly, as well as
patients with different comorbidities [3].
Roger Bone, in the 1990s, trying to explain why those
early clinical trials had failed, proposed the concept of the
‘‘Compensatory Antagonistic Response Syndrome
(CARS)’’, where he defended the idea that after the initial
explosive inflammatory response, an antagonistic anti-
inflammatory response would take place, leading sepsis
patients to succumb due to secondary infections or become
unresponsiveness to treatment interventions [4, 5] (Fig. 1).
Indeed, septic patients possess many signs of deficient
immune response, including ineffective antigen presenta-
tion, T-lymphocyte hyporesponsiveness, and decreased
Th1 cell proliferation; the term ‘‘immunoparalysis’’ is
commonly applied to this state of immune anergy observed
in late sepsis. As will be outlined in detail, the phenotype of
the septic patient is also characterized by increased num-
bers of apoptotic cells—mainly lymphocytes, dendritic
cells and epithelial cells. Since it is well established the
presence of apoptotic cells cause lymphocytes and mono-
cytes to significantly lesser amounts of pro-inflammatory
cytokines, the processes of cell death and immunosup-
pression are intricately related in sepsis.
Although some have proposed that organ failure and
immunosuppression in sepsis are a direct consequence of
apoptotic cell death, the diversity and complexity of the
clinical syndrome often make it difficult to ascertain which
phenomenon occurs first. Recent years have witnessed an
explosion in information regarding cell death mechanisms,
including they way they are induced and manipulated by
invasive bacterial pathogens. Here we will review some
key aspects of the tightly regulated pathways that govern
cell death decisions during the course of a septic insult. In
this context, an imprecision of the term immunoparalysis
can be appreciated, since apoptotic and counter-inflam-
matory pathways need to be continuously activated for the
perpetuation of this dynamic process.
Fundamental mechanisms of cell death relevant
to sepsis
Necrosis, apoptosis and autophagy
Dying cells can be necrotic, apoptotic (type-1 programmed
cell death), or autophagic (type-2 programmed cell death);
the latter phenomenon is often reversible. During necrosis,
cells exhibit swollen cytoplasm, disorganized organelle
structures, ruptured membranes and a lytic appearance to
their nuclei (karyolysis) [6]. In contrast, a hallmark features
of the apoptotic cell is chromatin condensation, which later
proceeds to fragmented nuclei (karyorrhexis) and forma-
tion of apoptotic bodies, often in the setting of an intact
plasma membrane and organelles. Autophagy is a process
that enables the cell to degrade self components in order to
recycle or eliminate excessive cytoplasmic content; in
critical situations like starvation, autophagy can preserve
cell life. Autophagy is characterized by formation of
autophagosomes—large double membrane vesicles that
engulf cytosol and organelles. Autophagosomes subse-
quently fuse with lysosomes, and are degraded without
further cell damage nor alarm signals [7]. It has been
suggested that once a cell’s autophagic capacity is over-
whelmed, apoptosis is triggered.
The three different modes of cell death appear to be
related mechanistically. The mitochondria, for example,
can be a promoter of autophagy, apoptosis or necrosis. The
resultant cell death pathway depends on the magnitude of
mitochondrial membrane permeability triggered during
Fig. 1 The balance of inflammation, and immunosuppression during
sepsis. In general, at an earlier stage, patients develop and
overwhelming inflammatory response (SIRS). Later, however, septic
patients show signs of anergy or immunosuppression with an
increased incidence of secondary infections (CARS). The elderly
and patients with comorbidities shift faster towart CARS, while
younger patients, generally, can present with prolonged SIRS. Both
conditions can culminate in multiple organ dysfuntion syndrome
(MODS). SIRS Systemic inflammatory response syndrome; CARS
compensatory antagonistic response syndrome
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stress by different factors, such as calcium ions, inorganic
phosphate and free fatty acids. Perturbations in perme-
ability can lead to ATP depletion and swelling or rupture of
the mitochondrial outer membrane. If permeability changes
are mild, an autophagy program can be summoned, recy-
cling the mitochondria before further damage ensues. If
cytochrome c and other pro-apoptotic molecules, like
apoptosis inducer-factor (AIF), second mitochondria-
derived activator of caspases/direct IAP-binding protein
(Smac/Diablo) and pro-caspases-2, -3, -8 and -9 reach the
cytosol, pathways that lead to apoptosis are activated. If
ATP drops precipitously, however, leading to plasma
membrane failure and leakage of intracellular enzymes,
necrosis occurs [8].
The inflammatory response to necrosis
The inflammatory response to necrosis remains a poorly
understood phenomenon. Injured cells release a variety
danger signals—some of these molecules are recognized
by receptors, stimulating the production of pro-inflamma-
tory mediators. The response mechanisms triggered by
necrotic cell death are particularly complex in sepsis. Since
even sterile cell death induces inflammation, a combination
of bacterial stimuli and host stimuli, even those elicited in
sterile sites, may be implicated in the inflammatory
response during a septic event. Furthermore, over time, if
apoptotic cells are not rapidly ingested by phagocytes, they
can undergo a process called secondary necrosis, releasing
their intracellular contents and inducing inflammation [9].
Although it is possible that cytokines might be released
directly upon cell death, only certain types of cells store
these molecules, so it is likely that other molecular inter-
mediates are also pivotal in this process. Many candidates
have been proposed, including HMGB1, uric acid, heat
shock proteins, DNA-chromatin complexes, antimicrobial
peptides, and others. HMGB1 is a nuclear protein expressed
constitutively, binding to DNA and regulating gene tran-
scription. It is released by necrotic cells, but not apoptotic
cells [10], and has been shown to stimulate TNFa secretion
by monocytes. While anti-HMGB1 antibodies injected into
mice were found to reduce inflammation in an animal model
of drug-induced hepatitis [10], necrotic cells lacking
HMGB1 are still capable of inducing inflammation [11].
Uric acid is an intracellular molecule whose biologically
active form, monosodium urate (MSU) microcrystals, is
generated upon release to the cytosolic compartment. MSU
has recently been identified as a strong inducer of IL-1b
secretion [12]. DNA-chromatin complexes [13] and heat
shock proteins [14, 15], have been shown to stimulate pro-
inflamatory cytokines production in certain conditions, and
cationic antimicrobial peptides [16] and various purine, such
as adenosine and ATP [17], also have chemotactic activity.
Specific receptors involved in amplifying the host
inflammatory response in response to cell necrotic are
beginning to be identified. Toll-like receptor 3 (TLR-3),
best recognized as a receptor for viral double-stranded
RNA, allows macrophages to recognize byproducts of
necrotic (but not apoptotic) neutrophils, thereby stimulat-
ing the generation of pro-inflammatory cytokines [18].
Another recent example of a receptor involved in this
process is macrophage-inducible C-type lectin (Mincle),
which has been shown to sense nonhomeostatic cell death
and induce the production of proinflammatory cytokines,
driving neutrophils to damaged tissues [19].
Caspase-dependent apoptotic cell death
Apoptotic cell death holds particular importance in sepsis
because it affects immune cells, which are critical during
the course of infection. Regulation of cell death is an
essential aspect of the host response to infectious stress and
is therefore maintained under tight control; caspases are the
principle orchestrators of these decision points. Over a
dozen caspases have been identified and approximately
two-thirds have been suggested to function in apoptosis
[20]. Many caspases also participate in additional cellular
functions, as cytokine production, differentiation and pro-
liferation [21]. Caspases are cysteine proteases activated
during apoptotic death and are highly conserved through
evolution, from humans to insects. Synthesized as enzy-
matically inert zymogens, caspases are composed of three
domains: an N-terminal domain, a p20 and a p10 domain,
the mature enzyme being a heterotetramer containing two
p20/p10 heterodimers and two active sites. Activated by
proteolytic cleavage, initiator caspases start an avalanche
of increasing caspase activity by processing and activating
effector caspases [22]. Effector caspases then cleave and
inactivate vital cellular components, such as DNA syn-
thesis, cleavage and repair enzymes, MDM2 (an inhibitor
of p53), cell cycle regulators, cytoskeletal proteins and
protein kinase Cd [23, 24].
There are three pathways for induction of apoptotic cell
death that culminate in caspase activation: the death-
receptor pathway, the mitochondrial pathway and the
endoplasmic reticulum pathway. The death receptor path-
way (also known as extrinsic pathway) is initiated on the
plasma membrane by ligand binding, followed by receptor
oligomerization. Ligands include proteins as Fas and
TNFa. The best characterized death receptors are CD95
(Fas or ApoI) and TNFRI (p55 or CD120a) [25]. Signaling
by some death receptors, like TNFRI, also mediates dif-
ferent biological outcomes, like inflammation, depending
on cell type, genetic and environmental factors [26]. Once
Fas (CD95) aggregates, it can recruits FAS-associated
death domains (FADD) to form membrane-bound
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complexes. These complexes recruit procaspase-8, the low
intrinsic protease activity of this enzyme being considered
enough to allow the various molecules recruited to the
same site to activate each other, ultimately leading to
caspase-3 activation and cell death. TNFRI oligomeriza-
tion, however, initially recruits RIP1, TRADD, TRAF2 and
cIAP1 to form complex I, which tranduces signals leading
to NF-jB translocation to the nucleus. At later time points,
RIP1, TRADD and TRAF2 dissociate and TNFRI recruits
FADD and caspase-8 to form complex II, which induce
apoptotic cell death [26] (Fig. 2).
The mitochondrial pathway is triggered by cell stress,
which leads to activation of proapoptotic members of the
Bcl-2 family, such as Bim, Noxa, Puma, Bid and Bad.
These events, in turn, sequestrate antiapoptotic Bcl-2
family members, including Bcl-2, Mcl-1, Bcl-XL, thereby
enabling Bax and Bad oligomerization. The three dimen-
sional structure of Bcl-xL reveals structural similarities to
bacterial pore-forming toxins [27] and it has been shown
that Bcl-2, Bcl-xL and Bax can form ion channels [28, 29].
Indeed, activated Bax and Bad form pores in the mito-
chondrial membrane, inducing the release of pro-apoptotic
molecules from the mitochondria, such as cytochrome c,
Smac/Diablo, IAP (inhibitor of apoptosis protein), AIF
(apoptosis-inducing factor), Omi/HtrA2 and endonuclease
G. When cytochrome c enters in the cytosol, it is able to
activate caspase-9 and, in conjunction with APAF-1 and
dATP, form a complex called the apoptosome, which
finally activates caspase-3, reaching the point where the
extrinsic and intrinsic pathways of apoptosis converge.
Smac/Diablo promotes apoptosis indirectly, by binding to
and antagonizing members of the inhibitors of apoptosis
protein (IAP) family [30]. Apoptosis-inducing factor (AIF)
and endonuclease-G induce apoptosis in a caspase-inde-
pendent manner. On the other hand, many anti-apoptotic
molecules, such as Bcl-2, Bcl-X and Akt act to maintain
mitochondrial integrity, keeping the pro-apoptotic mole-
cules inside. Indeed, a number of proteins with structural
similarity to Bcl-2 have been discovered in the last decade.
The link between the extrinsic and intrinsic pathways
occurs when caspase-8 cleaves Bid to t-Bid, which is then
able to translocate into mitochondrial membranes and
promote oligomerization of Bax.
Endoplasmic reticulum (ER) stress may ultimately lead
to cell death. Endoplasmic stress is induced by accumula-
tion of unfolded protein aggregates or excessive protein
trafficking. The precise function of caspase-12 in this
pathway has been investigated with conflicting results [31,
32]. Caspase-12 activates caspases-3, -8 and -9, and is itself
activated by Ca?2 and oxidant stress [33]. Caspase-12-
deficient mice clear bacteria more efficiently than wild-type
controls and have an enhanced production of IL-1b and
IL-18, but not TNFa or IL-6. Thus, caspase-12 has been
proposed as a decoy caspase, blocking caspase-1 activation
and increasing survival in septic shock [34]. Further studies,
however, are necessary to establish the role of caspase-12 in
endoplasmic reticulum stress-mediated apoptosis.
Caspase-independent apoptotic cell death
Although caspases regulate most apoptotic processes, there
are some exceptions. In particular, cathepsins can be
Fig. 2 Apoptosis pathways in
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responsible for apoptosis in a caspase-independent manner
[35, 36]. Cathepsins are mostly cysteine proteases, even
though the term also includes serine proteases (cathepsins
A and G) and aspartic proteases (cathepsins D and E).
While caspases are localized predominantly in the cyto-
plasm, cathepsins reside inside the lysosomes. Cathepsins
are involved in a number of important processes, including
intracellular protein turnover, antigen processing, propro-
tein and hormone activation [37, 38]. Cathepsins are
synthesized as inactive proenzymes and when released into
the cytoplasm, they can catalyze enzymatic cleavage of
different vital substrates, inducing apoptotic cell death.
Cathepsins B, L and D have been found to play an
important role in the regulation of apoptosis [39]. Lyso-
somal permeabilization seems to be induced by different
mechanisms, depending on the cell type or stimulus.
Activation of TNFR-I, for example, results in production of
sphingosine, which induces lysosomal rupture [40]. Reac-
tive oxygen species damage have also been related to
lysosomal leakage [41]. Cathepsins may cause direct
mitochondrial damage, mediating cytochrome c release
and, in parallel, Bid and Bax activation. In addition,
cathepsins may catalyze the degradation of critical sub-
strates for cell survival. Importantly, while moderate
lysosomal rupture is associated to apoptotic cell death,
massive rupture was found to induce necrotic cell death
[42].
Bacterial pathogen influences on host cell death
pathways
Modulation of host cell apoptosis
Certain bacterial pathogens have developed strategies to
induce rapid apoptosis of host cells including phagocytic
cells, allowing them to reduce the release of pro-inflam-
matory signals and survive intracellular killing. A family of
pore-forming bacterial cytotoxins, including those elabo-
rated by the leading pathogens Streptococcus pyogenes,
Staphylcoccus aureus, and Listeria monocytogenes are one
class of agents triggering cell death phenotypes. For
example, S. pyogenes induces rapid, dose-dependent
apoptosis of neutrophils [43] and macrophages [44]. This
cell death pathway involves apoptotic caspases and
requires GAS internalization by the phagocyte. Analysis of
GAS virulence factor mutants, heterologous expression,
and purified toxin studies identify the pore-forming cyto-
lysin streptolysin ‘O’ (SLO) as necessary and sufficient for
the apoptosis-inducing phenotype. Ultrastructural evidence
of membrane remodeling, loss of mitochondrial depolar-
ization and cytochrome c release indicate a direct attack of
SLO on the mitochondria initiates the intrinsic apoptosis
pathway [44]. The net effect of the accelerated apoptosis
reduces bacterial killing, diminished pro-inflammatory
cytokine release, and increased bacterial virulence, while
caspase inhibition blocked macrophage apoptosis and
promoted bacterial clearance. GAS also elaborate the
potent heterocyclic peptide cytolysin streptolysin S (SLS)
[45] which can deplete host phagocytes and help promote
bacterial survival [46] through a proinflammatory, calpain-
dependent cell death pathway [47]
L. monocytogenes lyses the phagosomal membrane and
escapes into the cytosol to initiate an intracellular infection,
a process dependent on the pore-formin toxin listeriolysin
O (LLO). Subsequently, intracellular L. monocytogenes
induces LLO-dependent apoptosis in different cell types,
including hepatocytes [48], lymphocytes [49] and dendritic
cells [50]. LLO might insert into the mitochondrial mem-
brane, allowing release of cytochrome c or efflux of Ca2?,
activating calpain or caspases. S. aureus alpha-toxin,
structurally related to SLO and LLO, induces apoptosis in
epithelial cells through activation of both caspase-3 and
caspase-8 [51, 52].
Legionella pneumophila, the causative agent of
Legionnaire’s disease, induces caspase-3-dependent apop-
tosis in macrophages and alveolar epithelial cells, through
an effector delivered by the Dot/Icm type IV-like secretion
system [53]. In an immune evasion strategy targeting the
lysosomal pathway, the toxic metabolite pyocyanin, pro-
duced by P. aeruginosa, accelerates neutrophil apoptosis
by inducing lysosomal membrane rupture, mitochondrial
membrane permeabilization and caspase activation [54]. A
number of other Gram-negative bacterial pathogens pro-
duce the so-called cytolethal distending toxin (CDT),
which exhibits a DNAse 1-like activity that generates DNA
strand breaks and leads to G2 cell cycle arrest followed by
apoptosis in immune cells [55]. Finally, activation by
bacterial superantigen such as S. aureus enterotoxin B and
S. pyogenes can delete specific T and B cell populations
through increased apoptosis, contributing to the patho-
genesis of potentially fatal toxic shock syndrome [56–58].
Interestingly, there are certain situations were host cell
apoptosis may serve a beneficial function in immune
defense against infection. An example is the rapid apoptosis
of lung epithelial cells recognized during P. aeruginosa
pulmonary infection, which occurs through a Fas/Fas
ligand-dependent pathway [59]. Deficiency of Fas or Fas
ligand leads to reduced lung epithelial cell apoptosis in vitro
and in vivo, but these knockout mice are more susceptible to
development of fatal pseudomonal sepsis. Here death
receptor pathway-mediated apoptosis aids in P. auruginosa
clearance by segregation of the bacteria into apoptotic
bodies, which are rapidly phagocytosed by other cells, and
by Fas-mediated induction of cytokine and antimicrobial
peptide release, which can amplify the host immune
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response and effects extracellular killing of the pathogen
[59].
Pyroptosis and the inflammasome
Rapid macrophage death induced by Salmonella bacteria
resembles necrosis, but caspase-1 activation is intimately
related to this process, distinguishing it from any form of
accidental cell death [60]. This particular pro-inflammatory
programmed cell death, therefore, seems to be an alterna-
tive pathway for removing unwanted cells without aborting
the recruitment of additional cells or cellular functions
crucial to fighting infection. The term ‘‘pyroptosis’’ has
been proposed as a name for this process [61, 62]. Caspase-
1, as opposed to caspases -3, -8 and -9, is an inflammatory
caspase. This subclass of caspases involved in cytokines
processing and release, also includes caspases-4, -5, -11
and -12. Members of the NOD-receptor family, including
the NALPs, NAIP and IPAF, promote the assembly of
multiprotein complexes, called inflammasomes, which play
a key role in the activation of the inflammatory caspases.
These molecular platforms integrate cellular signals and
promote dimerization of inflammatory caspases, leading to
the formation of active proteins, the processing of IL-1b
and IL-18, and the initiation of additional signaling
pathways.
Caspase-11 has been suggested to act as an essential
activator of caspase-1 and as its obligate partner [63].
Indeed, caspase-11 deficient mice were unable to produce
IL-1b and IL-18 in response to LPS stimulation [64]. This
requirement, however, seems to be stimulus-specific, since
caspase-1 could be activated normally in the absence of
caspase-11 following Listeria infection [65]. The human
caspase-1 gene cluster contains caspase-1 and four addi-
tional genes encoding decoy caspases: cop, inca1, inca2
and iceberg, which presumably play a role in negatively
regulate processing of pro-IL-1b; these decoy receptors are
absent in the mouse genome [66].
The NALP inflammassomes are the best studied so far,
and two types have been identified. The NALP1 inflam-
masome is composed of NALP1, the adaptor protein ASC,
caspase-1 and caspase-5, whereas the NALP2/NALP3
inflammasome composed of NALP2 or NALP3, plus
CARDINAL, ASC and caspase-1, but not caspase-5 [67].
Each NALP inflammasome can sense both pathogen-rec-
ognition patterns and danger-associated molecular patterns
[68]. Low concentrations of potassium are associated with
inflammasome activation, independent of the primary
stimulus. Indeed, pore-forming bacterial toxins such as
Staphylococcus aureus a-toxin activate the inflammasome
in a potassium-dependent manner [69]. Franciscella and
Listeria, through a type III-secretion system or the pro-
duction of pore-forming toxins, are also able to gain entry
into the cytosol and activate caspase-1 [70]. Cytoplasmic
NALP inflamassomes can detect intracellular infection
through recognition of molecular patterns, cooperating
with Toll-like receptors (TLRs) pathways to generate an
appropriate response to pathogens or cellular stress [71].
Important intracellular crosstalk occurs between TLRs
and the inflammasomes. While the first stimulus (TLR-
dependent) seems important for generation of pro-IL-1b,
the second one allows caspase-1 activation and subsequent
proteolytic maturation and secretion of IL-1b. Salmonella
[72] and Legionella [73], however, induce assembly of the
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IPAF inflammasome, while the anthrax lethal toxin is
recognized by the NALP1 inflammasome [74]. Thus,
depending on the context, the activity of caspase-1 can
induce cytokine secretion or cell death [75]. Caspase-1
activation needs to be maintained under tight regulation to
control the magnitude of the inflammatory response,
avoiding its deleterious effects, such as occurs in sepsis.
Supporting this notion, it has been shown that both cas-
pase-1 and caspase-11 deficient mice are more resistant to
endotoxic shock than wild-type controls [64, 76].
Induction of neutrophil extracellular trap-associated
cell death
Neutrophil extracellular traps (NETs) are structures com-
posed of chromatin and granule proteins that are released
as the cell dies, allowing neutrophils to entrap and kill
microorganisms extracellularly ‘‘postmortem’’ [77]. In this
new form of cell death [78, 79], colloquially dubbed
‘‘NETosis’’, the nuclei of neutrophils lose their shape, the
nuclear membrane disintegrates, and the chromatin comes
into direct contact with the cytoplasm, thus homogenizing
with the granular proteins. Subsequently, the cell mem-
brane breaks and NETs are released, trapping bacteria in
tissues and in the circulation, particularly in the hepatic and
pulmonary sinusoids. Indeed, with their lower shear stress
and smaller cross-sectional areas, sinusoids appear to serve
as an optimal site for NETs formation. Moreover, platelet
binding to neutrophils is critical for neutrophil activation
and further NETs formation in these vessels [80, 81]. This
process of NETosis is distinct from necrosis or apoptosis,
and neither apoptosis nor necrosis induced NET formation.
NETs show disintegration of the nuclear envelope, mixing
of nuclear and cytoplasmic material, loss of internal
membranes and disappearance of cytoplasmic organelles;
yet in NETs, there is no DNA fragmentation, a hallmark of
apoptosis. Differently from the classical forms of cell
death, It remains unclear why only granular proteins, but
not cytoplasmic proteins, bind to NETs. Released NETs
bind fungi, Gram-positive and Gram-negative bacteria [82,
83]. NET formation depends on generation of reactive
oxygen species, and consequently patients with NADPH
oxidase deficiency (chronic granulomatous disease) exhibit
a deficiency in NET formation that may further contribute
to their predisposition to severe and chronic infections.
The presence and kinetics of free circulating neutrophil-
derived DNA/NETs appear to serve as a useful marker of
sepsis disease severity and multiple organ failure in
patients following multiple traumas [84]. Specific bacterial
products, such as the surface expressed M protein of S.
pyogenes, or host chemokines, such as IL-8, can induce the
production of NETs [85, 86]. It is now recognized that
certain leading leading bacterial pathogens, including
Streptococcus pneumoniae and S. pyogenes, express broad-
spectrum DNAses that have recently been shown to dis-
solve NETs, allowing pathogen to escape entrapment and
spread to produce systemic infection in the host into the
host [87–89].
Cell death influences on sepsis progression
and immune suppression
As described in the introduction, the initial hyperinflam-
matory response in the first 24–72 h of sepsis is followed
by a protracted state of immunosuppression where failure
to eradicate the inciting infection and secondary nosoco-
mial infections, often with opportunistic pathogens such as
Pseudomonas aeruginosa or Candida albicans, are fre-
quent clinical manifestations. Coincident with this state of
diminished immune function, autopsies of septic patients in
adult, pediatric and neonatal age groups have revealed
extensive apoptosis of splenic lymphocytes [90–92].
Lymphocyte apoptosis is also appreciated as an early event
in peripheral blood of septic patients, with the degree of
apoptosis correlating to the severity of sepsis symptoms,
and profound and persistent lymphopenia a harbinger of
poor outcome [93]. Lymphocyte populations depleted
through apoptosis in septic patients include B cells and
CD4 ? T cells [90]. Apoptotic loss of splenic follicular
dendritic cells is also apparent, however, macrophages
populations are notably preserved [94]. Corroborating the
human findings, in experimental cecal ligation and punc-
ture (CLP), a well-established model system for the study
of polymicrobial sepsis in the mouse, apoptosis is induced
in the spleen, thymus, lung and intestinal Peyer’s patches
[95, 96]. By analysis of responses in endotoxin-sensitive
and -resistant mice, these studies identified the widespread
apoptosis of sepsis to occur through an LPS-independent
pathway(s). In addition to depletion of lymphocytes, sepsis
induces apoptosis of a large number of epithelial cells. Gut
[97], lungs [98] and liver [99] are the predominant organ
sites of increased epithelial cell apoptosis; endothelial cells
in these tissues are affected to a certain extent as well
[100].
It has been suggested that apoptosis can contribute to the
state of immunosuppression in prolonged sepsis in at least
two major fashions: the programmed cell death of key
effector cells, as described above, or alternatively, the
capacity of apoptotic cells to induce anergy and Th2-
responses in surviving immune cells such as macrophages
and dendritic cells [101]. When macrophages or dendritic
cells phagocytose apoptotic cells, both cell types express
lower levels of co-stimulatory molecules than expected
[102], while releasing large amounts of anti-inflammatory
cytokines such as transforming growth factor-beta (TGF-b)
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and IL-10 [103]; high levels of the latter cytokine a par-
ticularly poor prognostic factor in sepsis patients [104].
The TAM family of receptors (Tyro3, Axl, Mer tyrosine
kinase) are implicated in apoptotic cell recognition, as
compound deficiencies of these molecules result in defec-
tive apoptotic cell clearance, increased TNFa production,
and spontaneous hyperactivation of macrophages and
dendritic cells [105]. Other candidate’s receptors that may
mediate apoptotic cell recognition to suppress immune
responses include CD35, avb5 integrin, C1q and the
phosphatidylserine receptor [106].
In elegant adoptive transfer experiments using the CLP
model, parenteral administration of necrotic cells increased
IFN-c levels and decreased mortality, while administration
of apoptotic cells had the opposite effect, reducing IFN-c
levels and greatly increasing mortality [107]. In these
studies, the beneficial effects of necrotic cells were blocked
in IFN-c deficient animals or with anti-IFN-c antibodies
[107]. These results support the clinical evidence that the
pathways of cell death that transpires in early sepsis are
likely to exert profound influences on subsequent immune
competence and clinical outcome, with high levels of
apoptosis being particularly deleterious.
Mitochondrial dysfunction apparent during sepsis and
other critical illnesses contributes to a proclivity for cell
death and organ failure. In particular, nitric oxide (NO), a
proximal mediator of the inflammatory cascade in sepsis,
exerts inhibitory effects on mitochondrial electron trans-
port chain complexes. Histopathologic evidence in splenic
autopsies of septic patients suggests the mitochondrial
pathway plays a prominent role in lymphocyte apoptosis
[90]. Furthermore, skeletal muscle ATP concentrations
were significantly lower in patients with sepsis who sub-
sequently died than those who ultimately survived [108], a
finding which could be correlated to overproduction of NO
and depletion of cellular antioxidant capacity. In a rat CLP
model, oxidative stress within skeletal muscles develops
early in the onset of sepsis, leading to inhibition of active
mitochondrial respiration [109]. Bcl-2 transgenic mice,
which selectively overexpress an anti-apoptotic protein that
acts to preserve mitochondrial integrity, show improved
survival in the CLP model compared to normal mice [110].
Along with mitochondrial pathway, the death receptor
pathway also plays an important role in provoking lym-
phocyte apoptosis during sepsis. Mice with defects in the
Fas/Fas ligand signaling pathway through genetic engi-
neering or pharmacological blockade show decreased
levels of sepsis-induced lymphocyte apoptosis [111, 112],
as well as increased survival in the CLP model [113].
Furthermore, immunohistologic analyses and study of
caspase activation patterns in apoptotic lymphocytes iso-
lated from baboons with E. coli-induced septic shock [114]
as well as a large series of human sepsis patients [115] are
consistent with contributions from both the mitochondrial
and death-receptor pathways of apoptosis. However, inhi-
bition of B cell apoptosis by specific targeting of FccRII
(CD32), an ITIM-containing Fc receptor, was insufficient
to reduce mortality in the mouse CLP model, despite
leading to a significant drop in apoptotic cells numbers
[116]. Thus it is likely that B cell numbers need to be
dramatically reduced in sepsis to affect overall survival; the
anti-inflammatory response triggered in T cells following
their interacting with apoptotic B cells, while poorly
understood, could help explain this apparent paradox.
Therapeutic perspectives on cell death pathways
in sepsis
Based on the animal studies and on patients findings
observed until now, abrogation of apoptosis during sepsis
seems to be an interesting therapeutic strategy, in order to
prevent death of immune cells and maintain the integrity of
the mucosal surface. However, sepsis is a complex disease
and only specific subpopulations might benefit form dif-
ferent therapeutic strategies or the introduction of a certain
therapy at different time points. Indeed, in the clinical
setting, very few treatments have been proven to provide
significant benefit so far. Administration of insulin [117]
and activated protein C [118] are among these established
therapies. Interestingly, these treatments have the theoret-
ical potential to target apoptotic pathways, and it is likely
reduced apoptosis may contribute to their therapeutic
benefit [119]. For example, in addition to its anti-inflam-
matory effect, administration of insulin to septic patients
can induce cell proliferation, probably by activation of Akt/
PKB pathways [120]. Activated protein C has similarly
been shown to counter the induction of apoptosis in animal
studies and in vitro studies in human endothelial and
monocyte cell lines [121, 122].
Caspase inhibition has been a focus of anti-apoptotic
therapy in sepsis with encouraging results in animal models.
Treatment with z-VAD (N-benzyloxycarbonyl-Val-Ala-
Asp(O-methyl) fluoromethyl ketone), a broad-spectrum
caspase inhibitor, improves the survival of septic mice
[123]. The administration of siRNA directed against the
caspase-8 gene transcript also improves survival in the
mouse CLP model [111]. However, there are important
theoretical and pharmacological considerations that may
limit the utility of caspase-targeted approaches. First, since
only a very small amount of activated caspase-3 can initiate
DNA fragmentation and apoptosis, the pharmacological
blockade would have have to be highly potent and penetrant
[101], while caspase inhibitors at large doses can have non-
specific side effects including cytotoxicity. Anti-retroviral
protease inhibitors have also been tested in murine sepsis
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and shown to increase survival, reduce lymphocyte apop-
tosis, early TNFa and late IL-6 and IL-10 levels [124].
Targeted with the death receptor pathway is another
intriguing approach to ameliorate sepsis-associated apop-
tosis and immune dysfunction, especially since high levels
of Fas expression are evident in the tissues of septic ani-
mals. In mouse CLP studies, inhibition of Fas signaling
using a Fas-based fusion protein (FasP, Amgen, Inc.) to
block receptor ligation reduced lymphocyte apoptosis,
improved organ blood flow, prevents hepatic injury, and
reduces mortality [113, 125]. The results on blocking
lymphocyte apoptosis and hepatic injury have been repro-
duced in an approach employing siRNA targeting Fas [111].
Finally, the pharmacological targeting mitochondrial
reactive oxygen species (ROS), whose production is char-
acteristic of early stages of apoptosis, offers another potential
therapeutic approach to reduce sepsis-induced cell death.
Nitroxides, such as 4-hydroxy-2,2,6,6,-tetramethyl piperi-
dine-1-oxyl (TEMPOL) act as effective ROS scavengers and
provide a cytoprotective activity in experimental models of
oxidative stress [126]. A derivative of TEMPOL coupled to
gramicidin S for mitochondrial targeting was protective in a
rat model of lethal hemorrhagic shock, blocking activation of
the pro-apoptotic caspases -3 and -7 [127]; extension of these
studies to sepsis models would appear to hold merit.
Conclusions
Sepsis is an exaggerated and detrimental inflammatory
response reflecting the host’s desperate attempt to control
an overwhelming infection. Within septic patients, specific
cell populations are dying, and indeed so are the patients
themselves. However, with the advent of antibiotic therapy
and modern intensive care procedures for life support,
physicians are in a position to rescue more sepsis patients
through improved understanding of the fundamental path-
ophysiology, including the prominent role of cell death.
While apoptosis has been the major focus of investigative
attention, necrosis, pyroptosis and extracellular trap-asso-
ciated cell death certainly also play important role in this
disease. Indeed, a variety of modalities of cell death co-exist
in septic patients and the ultimate clinical phenotype is the
result not only of the cell populations lost, but also of the
proinflammatory and antiinflammatory effects of necrotic
and apoptotic cells (respectively) on macrophage and den-
dritic cell function (Fig. 3). Moreover, specific virulence
factors expressed by individual inciting bacterial patho-
gen(s) may skew the frequency and distribution of cell
death phenotypes and thus the tempo and severity of illness.
It is apparent that cell disintegration, and the molecules
thereby released, plays a governing roles in the inflamma-
tory response and host immune competence during sepsis.
Comprehension of the molecular mechanisms implicated in
this phenomenon might lead to the development of thera-
peutic strategies targeted against dying cells and the signals
they transmit, thereby mitigating their negative effects.
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